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Epstein-Barr virus (EBV), the causative agent of infectious mononucleosis, plays a significant role as a cofactor in
the process of tumorigenesis, and has consistently been associated with a variety of malignancies especially in
immunocompromised patients. Forty-four children and adolescents (21 liver transplant patients, 7 heart transplant,
5 AIDS, 3 autoimmune hepatitis, 2 nephritic syndromes, 2 medullar aplasia, 2 primary immunodeficiency disorder
patients, 1 thrombocytopenic purpura and 1 systemic lupus erythematosus) presenting with chronic active EBV
infection (VCA-IgM persistently positive; VCA-IgG > 20 AU/mL and positive IgG – EBNA) had peripheral blood
samples obtained during clinically characterized EBV reactivation episodes. DNA samples were amplified in order
to detect and type EBV on the basis of the EBNA-2 sequence (EBNA2 protein is essential for EBV-driven
immortalization of B lymphocytes). Although we have found a predominance of type 1 EBNA-2 virus (33/44; 75%),
10 patients (22.73%) carried type 2 EBNA-2, and one liver transplant patient (2.27%) a mixture of the two types, the
higher proportion of type 2 EBV, as well as the finding of one patient bearing the two types is in agreement with
other reports held on lymphoproliferative disorder (LPD) patients, which analyzed tumor biopsies. We conclude
that EBNA-2 detection and typing can be performed in peripheral blood samples, and the high prevalence of type 2
in our casuistic indicates that this population is actually at risk of developing LPD, and should be monitored.
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Epstein-Barr virus (EBV), the causative agent of infectious
mononucleosis, plays a significant role as a cofactor in the
process of tumorigenesis, and has consistently been
associated with a variety of malignancies including endemic
Burkitt’s lymphoma, nasopharyngeal carcinoma, certain B and
T-cell lymphomas, approximately 50% of Hodgkin’s disease,
different types of gastric carcinomas, and other
lymphoproliferative diseases [1]. Immunosuppressive drugs
such as cyclosporine A and tacrolimus seem to act
synergistically with EBV as tumor inducing factors [2].
EBV infection of primary B cells results in the
establishment of a latent infection, in which only 11 of
potentially more than 80 viral proteins are expressed. These
gene products include EBV nuclear antigens EBNA 1, 2, 3A,
3B, 3C and 5, latent proteins (LMP) 1, 2A and 2B, and small
non coding RNAs (EBER 1 and 2). The Epstein-Barr virus
EBNA-2 protein is a transcriptional activator that regulates
viral latent genes and cellular gene expression, and is also
essential for EBV-driven immortalization of B lymphocytes
[3,4]. EBNA-2 is critically required for B-cell transformation,
as the P3HR1-derived EBV strain, which lacks EBNA-2, is
deficient in this capacity, and the transforming potential is
reconstituted with EBNA-2 expression [5,6].
EBV type 1 and type 2 (formerly called type A and B),
appear to be mainly caused by divergence within the EBNA-
2 protein, because EBV type 2, when compared to type 1, has
a lower transforming efficiency and a poorer initial outgrowth
[7,8]. Both EBV types occur worldwide, with different
geographical distributions. In general, EBV type 1 is the
predominant type in lymphatic cells of immunocompetent,
infected individuals. However, in certain T-cell deficient hosts,
especially those with acquired immunodeficiency syndrome,
there are increased infection rates with EBV type 2 [9,10].
Persistent infection with more than one EBV type or strain
is not unusual, particularly in immunocompromised patients.
Intertypic recombinants have been identified in the oropharynx
and lymphocytes of immunodeficient patients, and less
commonly from healthy people. Scientific evidence suggests
that some immune impairment promotes co-infection with
multiple strains of EBV, and fosters the development of
intertypic recombinant viruses [10]. Human immunodeficiency
virus type 1-infected patients develop a number of
lymphoproliferative disorders ranging from non neoplastic
lymphadenopathies to B-cell lymphomas [11]. Different point
mutations in the EBNA-2 gene were described in some EBV
type-1 isolates from immunodeficiency virus-infected patients,
but not from immunodeficiency virus-negative subjects [12].
Although a large amount of in vitro scientific evidence
concerning the differences of EBNA-2 type 1 and type 2 is
available, little is known about whether both strains really
differ in their biological activities in vivo. Aitken et al. [13]
found EBNA-2 sequence heterogeneity in EBV type-1 isolates
from African and New Guinean endemic Burkitt’s lymphoma
cases, suggesting that variant EBV type-1 sub-strains may be
associated with these tumors.
Human EBV establishes latency and promotes the long-
term survival of its host B cell by targeting the molecular
machinery controlling cell fate decisions. EBNA-2 is a key
determinant in the EBV-driven B-cell growth transformation
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process. By activating the array of viral and cellular target
genes, EBNA-2 initiates a cascade of events which ultimately
cause cell cycle entry and the proliferation of the infected B
cell [14]. The mechanism of transcriptional activation by EBNA-
2 also involves phosphorylation of the C-terminal domain
(CTD) of RNA polymerase II [15]. It was also established that
somatic hypermutation and class-switch recombination in
germinal centers critically depend on activation-induced
cytidine deaminase (AID). Deregulation of AID may lead to
the aberrant activation or persistence of both genetic
processes, thus contributing to the pathogenesis of B-cell
lymphomas by mistargeted mutagenesis or recombination [16].
The EBNA-2 also up-regulates bfl-1, an anti-apoptotic gene
which confers protection from apoptosis under conditions of
growth factor deprivation [17].
Taken into account that conventional diagnostic tools are
rarely useful in evaluating EBV-related disorders in
immunodeficient patients, polymerase chain reaction (PCR)
offers the possibility of rapid and accurate EBV detection and
typing in patients at risk of developing lymphoproliferative
disorders, allowing a better understanding of the different
pathogenic potentials of the two main viral types [18]. Another
interesting point is to determine whether peripheral blood
leukocytes could be used as the primary source of DNA
instead of biopsy specimens, which would allow pediatricians
to monitor immunocompromised patients with chronic-active
infections by means of a less invasive procedure, as soon as
EBV detection takes place. Therefore, we aimed at detecting
and typing the EBV EBNA-2 gene in a group of
immunocompromised children and adolescents by analyzing
peripheral blood samples.
Material and Methods
This study was approved by the Ethics Committee of the
“Faculdade de Medicina da Universidade de São Paulo”,
Brazil. After informed consent, we analyzed peripheral blood
samples of 44 immunocompromised patients presenting with
chronic-active EBV infection. These patients, 24 boys and 20
girls, from 5 to 14 years old, were assisted at the Children’s
Institute: 21 with liver transplants, 7 with heart transplants, 5
with AIDS, 3 with autoimmune hepatitis, 2 with nephritic
syndromes, 2 with medullar aplasia, 2 with primary
immunodeficiency disorders, 1 with thrombocytopenic
purpura and 1 with systemic lupus erythematosus. All 44 cases
were diagnosed as bearing chronic-active EBV infection on
the basis of serological results: VCA-IgM persistently
positive; VCA-IgG > 20 AU/mL and positive for IgG – EBNA.
IgG antibodies to VCA were determined by capture ELISA
(Diasorin, Italy); VCA-IgG positive > 20 AU/mL and VCA-
IgM positive (qualitative test); IgG to EBNA (nuclear antigen)
was determined by ELISA (Sanofi Diagnostics Pasteur,
France), samples being classified as acute EBV infection
(positive for IgM and IgG to VCA but negative to IgG-EBNA),
post-acute EBV infection or carrier state (positive for IgG to
VCA and IgG –EBNA).
DNA Extraction from Whole Blood
Two milliliters of whole blood (EDTA, Becton Dickinson)
was drawn from patients after informed consent of parents. DNA
extraction was performed according to a previously described
salting-out protocol [19]. DNA concentration was estimated by
UV spectrophotometry at 260 nm (DU-70, Beckman).
Amplification and Detection
Before EBV specific amplifications, all DNA samples were
tested with primers to amplify a fragment of the human beta-
actin gene (sense 5’- GTGGGGCGCCCCAGGCACC-3’ and anti-
sense 5’–CTCCTTATT GTCACGCACGATTTC-3’) in order
to ensure DNA integrity and absence of amplification
inhibitors. PCR assays were performed in 50 µL of total volume
containing approximately 100 ng genomic DNA, 100 mM Tris-
HCl, 500 mM KCl; 2.5 units Taq DNA polymerase (Amersham,
Biotech), 200 µM dNTP (Invitrogen, USA), 1.5 mM MgCl2; 0.4
µM each primer. In the first round of amplification, primers
E2p1 and E2p2 aimed at amplifying a fragment of 596bp
covering almost the entire EBNA2 gene extent (E2p1: 5’-
AGGGATGCCTGGACACAAGA-3’ and E2p2: 5’-
TGGTGCTGCTGGTG GTGGCAA T-3’). In the second round
of amplification, the pair of primers Ap1 and Ap2 aimed at
amplifying a 497 bp fragment characterizing the EBV type 1
EBNA2 gene product, while primers Bp1 and Bp2 amplified a
150 bp fragment specific to the EBV type 2 EBNA2 gene
product (Ap1: 5’- TCTTGATAGGGA TCCGCTAGGATA-3’;
Ap2: 5’-ACCGTGGTTCTGGACTATCTGGATC-3’; Bp1:5’-
CATGGTAGCCTTA GGACATA -3’; Bp2: 5’-
AGACTTAGTTGATGCCCTAG-3’) [18]. All amplifications
(beta-actin and EBV specific) were carried out as follows: after
an initial denaturation step of 5 min. at 950C, 40 cycles of
amplification were performed in either the first, or the second
round of amplifications (MJ Research, PT-150 minicycler).
Cycles consisted of 1 min. at 950C, 1 min. at 550C and 1 min. at
720C, followed by a final extension step of 5 min. at 720C.
Afterwards, 10 mL of amplification products were analyzed
using horizontal electrophoresis (Horizon H-58, Life
Technologies, USA), in 2% ethidium bromide-stained agarose
gel (Sigma, USA). In each experiment, a negative control
containing sterile water instead of genomic DNA, or DNA
from a non infected individual was tested, as well as a positive
control (EBV DNA from viral cultures).
Results
All 44 DNA samples were successfully amplified by the
human beta-actin primers thus confirming integrity of DNA
samples, and the absence of PCR inhibitors. The first round
of amplification was followed by the second PCR with EBNA-
2 type 1 and type 2 specific primers (Figure 1). From a total of
44 samples, there were 33 type 1 EBNA-2 virus (33/44 or 75.0%),
10 type 2 (10/44 or 22.73%), and one DNA sample belonging
to a liver transplant recipient patient which amplified type 1
and type 2 at the same time (01/44 or 2.27%). Table 1 summarizes
PCR detection and typing and the patients’ underlying disease.
Immunocompromised Children EBNA-2 Typing
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Table 1. Description of patients according to the underlying disease and the EBNA-2 typing by PCR.
Figure 1. Electrophoresis of the nested-PCR products. A- First round (external primers E2p1 and E2p2). M - molecular weight
marker - 100 bp (Amersham); lanes 1A, 3A, 5A and 7A – negative controls (sterile water instead of DNA); lane 2A- patient 1, lane
4A- patient 2; lane 6A- positive control (EBV-DNA). B- Second round (EBV type 1 and 2 specific primers, Ap1-2 and Bp1-2,
respectively). M - molecular weight marker - 100 bp (Amersham); lane 1B - negative control (sterile water instead of DNA); lanes
2B and 3B – Patient 1; lanes 4B and 5B – Patient 2; lane 6B - positive control (EBV type 1); lane 7A- positive control (EBV type 2).
Discussion
In Brazil there are three reports on the detection and typing
of EBV in pediatric patients. Araújo et al. [20] found type 1
EBV in the majority of Brazilian Burkitt’s lymphoma cases: 20/
30 type 1, 7/30 type 2 and 3 samples were not amplifiable.
More recently [21], the same group studied the phenotype
and the expression of EBV gene products in 90 classical
Hodgkin and non Hodgkin’s disease pediatric cases by
immunohistochemistry, and in situ hybridization. They found
that EBV infection was present in 86.7% of patients, but
exclusively in classical Hodgkin’s disease biopsies, although
associated with all EBV subtypes. Hassan et al. [22] compared
an EBV-RNA (EBER) in situ hybridization assay with a nested-
PCR that aimed at typing the EBNA-2 gene in 41 children
presenting with B-cell non Hodgkin’s lymphoma, including
35 Burkitt’s lymphomas. They successfully detected EBV
genomes in 68% of biopsies, and type 1 and type 2 EBV
accounted for 80 and 20% of the samples, respectively. PCR
and in situ hybridization were concordant in 95% of results.
We studied 44 children and adolescents presenting with
severe underlying diseases and receiving immunosuppressive
therapy. However, we did not investigate any patient with overt
lymphoproliferative disorders. Nevertheless, our findings
corroborate those of Hassan et al. [22] as we found very similar
distribution of type 1 and 2 EBNA-2: 75% of type 1; 22.73% of
type 2 and 2.27% of simultaneous infection (type 1 and type 2).















Disease N Type 1 Type 2 Type 1 and 2
Liver transplantation 21 15 5 1
Heart transplantation 7 6 1 0
AIDS 5 2 3 0
Autoimmune hepatitis 3 3 0 0
Nephritic syndrome 2 2 0 0
Medullar aplasia 2 2 0 0
Primary immunodeficiency 2 2 0 0
Thrombocytopenic purpura 1 1 0 0
SLE 1 0 1 0
Total 44 33 10 1
www.bjid.com.br
BJID 2008; 12 (June) 189
Norin et al. [23] studied the incidence of
lymphoproliferative disorders (LPD), in a series of 500 liver
transplantations. They found that the rate varied from 1 to
10% depending on the type of organ transplanted, and the
immunosuppressive regimens used. They concluded that post
transplant LPD constitute a significant cause of complication.
In the present study, there was a predominance of type 1
EBNA-2 EBV among the 21 liver transplant patients studied
(15/21 or 71.43%), with type 2 found in 5/21 patients (23.81%),
and both types in one patient (1/21 or 4.76%). Whether EBV
typing will be useful in preventing, and promoting early
diagnosis of LPD in these patients has yet to be verified.
EBV causes a wide spectrum of diseases in the setting of
immunodeficiency including primary or secondary (acquired)
immunodeficiencies, which have been increasingly reported
[24]. The major clinical phenotype is the EBV genome-positive
LPD, which ranges from benign lymphoproliferation to
malignant lymphoma with chromosome alterations. Severe or
fatal infectious mononucleosis may develop in some patients
with immunodeficiency disorders such as X-linked diseases.
Canioni et al. [25] evaluated distinctive features of LPD in a
group of 18 primary immunodeficiency patients and compared
the findings with those of 10 post transplant children. They
concluded that LPD is much more pleomorphic in primary
immunodeficiency patients compared to post transplant
recipients, even if some LPD are similar in both groups. A low
T-cell count and abnormal T-cell function indicated bad
prognosis in both groups. Polymorphic LPD were most
frequent (n=19), whereas lymphomas were rare (n=7), and
pseudo-tumoral lymphoid hyperplasia (n=2) was only
observed in the group of primary immunodeficiency patients.
Several reports have demonstrated that the responses of B-
cells to the Epstein-Barr virus are highly heterogeneous in
common variable immunodeficiency. Kondo et al. [26] have
studied patients with selected primary immunodeficiency
disorders (Bloom’s syndrome, Wiskott-Aldrich Syndrome, IgA
deficiency). In Bloom’s Syndrome, a mild B-cell function
abnormality was found, while in the Wiskott-Aldrich’s patients
responses were variable. In a patient with IgA deficiency,
peripheral blood mononuclear cells responded adequately to
EBV in terms of proliferation, but poorly in IgA production,
suggesting an abnormality only in the IgA production
mechanism. Unfortunately, none of the mentioned studies have
determined EBV type 1 and type 2 prevalence. In our casuistic,
we have included only two patients with primary autoimmune
deficiency, and in both cases the classical EBNA-2 type 1 was
found. EBNA-2 and LMP1 gene analysis of 48 LPD from HIV-
1 patients evidenced EBNA-2 transcripts in all tumors, 50% of
samples were co-infected with both EBV type 1 and 2 strains
and/or a multitude of type 1 variants, with predominance of
type 1 in large cell lymphomas, and type 2 in Burkitt-like tumors
[11]. In our study, the five AIDS patients included did not
present with LPD, but were undeniably at-risk patients.
Although we observed a predominance of type 2 virus (2
type 1, and 3 type 2 EBNA-2), further studies with more AIDS
patients are needed to confirm this finding. Furthermore, we
did not find any AIDS patient presenting with both EBV types.
Kanegane et al. [27] have associated cases of acute idiopathic
thrombocytopenic purpura with primary EBV infections. More
recently, Yenicesu et al. [28] conducted a retrospective study
based on the medical notes of pediatric patients with idiopathic
thrombocytopenic purpura in whom EBV, CMV and rubella
virus serology were performed, and viral infection was detected
in 13.3% of cases. These studies did not analyze the EBV
infection at the molecular level. In our study group, only one
patient with idiopathic thrombocytopenic purpura was
included, and had a type 1 EBV virus.
EBV infection can cause a number of renal disorders
ranging from microscopic hematuria, to acute renal failure.
Membranous nephropathy is an uncommon and usually
secondary cause of nephritic syndrome in children, and has
been reported after chronic EBV infections with persistent
antigenemia. Araya et al. [29] reported two pediatric cases of
secondary membranous nephropathy associated with acute
and chronic EBV infection. The association of EBV with renal
histological changes consistent with membranous
nephropathy has been previously suggested, but not directly
described. In the study performed by Araya et al. [29] EBV
infections were not detected and typed by PCR, so that they
cannot state what type of EBV was at the origin of infections.
In our study, the two patients with nephritic syndrome analyzed
had type 1 EBNA-2 virus. In addition, to examine the possible
involvement of EBV in the etiology of renal cell carcinoma
(RCC), 9 RCC, 2 nephroblastoma (Wilm’s tumor), and 2 RCC
cell lines were subjected to mRNA in situ hybridization and
indirect immunofluorescence staining. It was found that EBV
infected all the RCC and nephroblastoma patients irrespective
of the histological or clinical stage. The results also suggest
that EBV expression may be involved in the pathogenesis of
RCC and nephroblastoma [30].
To investigate the possibility that Epstein-Barr virus might
play a role in systemic lupus erythematosus (SLE), EBV was
searched for by PCR and by culture isolation in oropharyngeal
lavage fluids of 15 SLE patients, of 13 acute infectious
mononucleosis patients, and of 28 healthy individuals. EBV
type 1 DNA was demonstrated by PCR in the oropharyngeal
secretions of 8 SLE patients, and the virus was isolated from
6 DNA-positive specimens. Moreover, 50% of the SLE patients,
and 100% of the infectious mononucleosis patients, but none
of the EBV-seropositive normal individuals, produced IgG
antibodies raised against synthetic EBNA-2 peptides used in
the study. The authors concluded that EBV may establish a
persistent infection, at least in a certain number of SLE patients
[31]. We have analyzed only one DNA sample from a SLE
patient undergoing prolonged immunosuppressive therapy,
and experiencing an EBV reactivation episode at the time of
blood sampling. The nested-PCR to type the EBNA-2 gene
found a type 2 virus in this patient. Again, it is premature to
affirm the predominance of a certain subtype of EBV based on
one SLE case, but it is important to emphasize that in the
Immunocompromised Children EBNA-2 Typing
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totality of patients included in the present study, it was
possible to detect and type EBV using DNA extracted from
peripheral blood samples drained during clinically characterized
reactivation episodes.
Our nested-PCR technique has successfully detected and
typed all 44 samples included in the present study probably
because all patients were correctly diagnosed as having
chronic-active EBV infection, and the samples were drawn
from patients during reactivation episodes. Kunimoto et al.
[32] have used a one-step amplification targeting the gene
encoding the EBNA-2 nuclear antigen. EBV was detected in
mouth washings of 21 (23%) out of 91 seropositive healthy
adults. Twenty samples (22%) contained type 1, and only one
(1%) type 2. Seventy-nine patients with various types of
tonsillitis were also studied. EBV was detected in mouth
washings of 37 patients (47%): 34 (43%) were type 1, and 3
(4%) were type 2. Double infection was not seen in either
group. They concluded that EBV type 1 was the dominant
type in Japan, and that the type 2 variant was quite rare. More
recently, Peh et al. [33] aimed at comparing the performances
of a one-step and a nested-PCR to detect the EBNA-2 gene.
They studied 38 paraffin-embedded tissue lymphomas and 14
nasopharyngeal carcinomas, along with 12 reactive lymph
nodes and tonsils as normal controls. All cases showed
presence of type 1 (called type A) virus, consistently detected
by nested-PCR, but not with the one-step amplification. They
did not find any type 2 (called type B) samples, or mixed
infection in the casuistic. They concluded that the nested-
PCR technique used had successfully increased the
sensitivity of EBV detection and typing, and type 1 EBV was
the prevalent strain associated with human diseases in
Malaysia.
In our casuistic we found a predominance of type 1 EBNA-
2 virus among the 44 samples studied, corresponding to 75.0%
of the total. However, 22.73% of samples carried type 2 EBNA-
2 virus, and 2.27% a mixture of the two types. The fact that the
casuistic was composed of immunocompromised children and
adolescents could account for the higher proportion of type 2
EBV with respect to studies conducted in healthy populations.
When these results are compared with those of LPD bearing
patients, the prevalence of type 1, type 2, and both types, are
similar, indicating that our population is actually at risk of
developing LPD.
Strategies for the prophylaxis and treatment of these
potentially life-threatening complications of EBV infection
have advanced dramatically. They include immunological-
based approaches targeted at EBV-infected cells, as well as
improvement in the treatment of the underlying and
predisposing diseases [34]. EBV detection and typing might
also contribute to these strategies at a diagnostic and
prognostic level.
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